Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...

Feel the power of the BMW M6 F12 Cabrio on the Autobahn. Experience the kickdown acceleration, V8 sound, and dynamic performance of this convertible in action. Plane crash kills more than 150 in ...

In effect, this makes the Level 3 system functional on all 8,196 miles of the country's autobahn network, Mercedes-Benz notes, allowing the driver to text or even watch videos on their phone or ...

(RTTNews) - Cara Therapeutics, Inc. (CARA), Wednesday announced that the company has entered into a merger agreement with Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other ...

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...

Century Therapeutics entered the partnership three years ago. Bristol Myers Squibb is ending its drug development partnership with Philadelphia cell therapy company Century Therapeutics ...

Shares of CRISPR Therapeutics have struggled amid less-than-stellar sales of its Casgevy therapy. The company's gene-editing biotechnology holds much promise but still faces significant uncertainties.

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

TScan Therapeutics stock opened at $3.02 on Tuesday. The company has a market capitalization of $161.18 million, a price-to-earnings ratio of -2.85 and a beta of 0.79. TScan Therapeutics has a 1 ...

Keros Therapeutics paused 3.0 mg/kg and 4.5 mg/kg dosing in the TROPOS trial due to adverse pericardial effusion events. Dosing at 1.5 mg/kg continues; topline data for all arms expected in Q2 2025.